Jump to: Page Content, Section Navigation, Site Navigation, Site Search, Account Information, or Site Tools.
|
|
Research News
The hormone estrogen is both a villain and a savior, thought to contribute to the development of breast and uterine cancers but also to protect women against heart attacks and osteoporosis. Now a study of an estrogenlike drug, reported on page 1222, may help explain the hormone's contradictory personality and open the way to designing drugs that block only its unwanted effects--or mimic only its beneficial ones. The drug, called raloxifene, sends its signals to the genes by different pathways depending on the tissue it is acting on. The natural hormone may owe its many guises to a similar variety of pathways.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
|
Science. ISSN 0036-8075 (print), 1095-9203 (online)